Modern Diagnostic SME IPO GMP Todays is flat at ₹14 on 07 January 2026, indicating a neutral sentiment in the grey market. Based on recent grey market activity, there has been 12.22% premium movement, and the GMP trend suggests upward movement.
With the upper price band fixed at ₹90 per share, the estimated listing price also stands at ₹104, reflecting no expected gain or loss at this stage. Such a trend usually shows that the market is taking a wait-and-watch approach, especially when the IPO opening date is still some days away.
Contents
Modern Diagnostic IPO Day-Wise GMP Trend
The table below explains the day-wise GMP movement and its impact on the expected listing price. Since the GMP has remained unchanged, the estimated returns are also stable.
| Date | IPO Price | GMP | Estimated Listing Price | GMP Gain | GMP Trend |
|---|---|---|---|---|---|
| 30-12-2025 | ₹90 | ₹11 | ₹101 | 12.22% | Up |
| 29-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
| 28-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
| 27-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
| 26-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
| 25-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
| 24-12-2025 | ₹90 | ₹0 | ₹90 | 0.00% | No Change |
As seen above, the grey market has shown no upward or downward movement over the last few sessions. This suggests limited speculative activity and steady expectations around the IPO pricing.
Disclaimer: IPO GMP, Kostak, and Subject to Sauda (Sub2) rates are unofficial and shared for informational purposes only. We do not trade or recommend participation in the grey market. GMP is not a guarantee of listing performance. Investors should apply after reviewing the company’s fundamentals and official offer documents.
Modern Diagnostic IPO Details
Modern Diagnostic SME IPO is a book-built issue aiming to raise around ₹37 crore through a fresh issue. The IPO will be listed on the BSE SME platform.
| Particulars | Details |
|---|---|
| IPO Open Date | December 31, 2025 |
| IPO Close Date | January 2, 2026 |
| Face Value | ₹10 per equity share |
| Price Band | ₹85 to ₹90 per share |
| Issue Size | Approx ₹37 Crores |
| Fresh Issue | Approx ₹37 Crores |
| Issue Type | Book Build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
Modern Diagnostic IPO Important Dates
| Event | Date |
|---|---|
| IPO Open Date | December 31, 2025 |
| IPO Close Date | January 2, 2026 |
| Basis of Allotment | January 5, 2026 |
| Refunds | January 6, 2026 |
| Credit to Demat Account | January 6, 2026 |
| IPO Listing Date | January 7, 2026 |
Modern Diagnostic Business Overview
Modern Diagnostic & Research Centre Limited was established in 1985 and operates in the diagnostic and healthcare services segment. The company provides a wide range of radiology and pathology services, including MRI, CT scan, ultrasound, digital X-ray, laboratory testing, cardiology and neurology diagnostics.
It also offers home sample collection services for patient convenience. At present, the company operates 21 centres, including 17 laboratories and 4 diagnostic centres, spread across 8 Indian states.
Modern Diagnostic IPO GMP FAQs
What is Modern Diagnostic IPO GMP today?
Modern Diagnostic IPO GMP is currently ₹11, showing upward sentiment in the grey market.
What is the estimated listing price of Modern Diagnostic IPO based on GMP?
Based on the current GMP of ₹11 and the upper price band of ₹90, the estimated listing price is around ₹90 per share.
Can GMP change before the IPO listing?
Yes, IPO GMP can change anytime before listing based on subscription response, market sentiment, and broader SME market conditions.
Should investors rely only on GMP to apply for this IPO?
No, investors should not rely solely on GMP. IPO decisions should be based on company fundamentals, financial performance, valuation, and long-term business prospects.
Expert Comment
The upward GMP trend in Modern Diagnostic SME IPO reflects a cautious and orderly market outlook rather than weak demand. Grey market participants appear to be waiting for subscription data and broader SME market cues before taking positions.
Investors should avoid relying solely on GMP movements and instead focus on the company’s business stability, operating history, and valuation comfort while making an IPO investment decision.
